Product Images Fulvestrant

This is a chart that compares the combination of Fulvestrant and Palbociclib with Fulvestrant and Placebo. The X-axis shows the time in months, and the Y-axis shows the number of patients at risk. The chart illustrates the progression-free survival probability for each treatment. However, specific data and conclusions cannot be drawn from this image alone.*

This appears to be a graph or chart showing the overall survival probability of two treatments: Fulvestrant+palbociclib and Fulvestrant+placebo. It also includes the number of patients at risk and time in months.*

This is a table showing the number of patients in two groups (Fulvestrant plus Abemaciclib and Fulvestrant plus Placebo) and their observed censorship. There is also a survival curve for each group over a period of 30 months. The title of the table is "Censored observations."*

This appears to be a graph or chart with two groups: one receiving a combination of Fulvestrant and Abemaciclib (N=446) and another receiving Fulvestrant and Placebo (N=223). The x-axis indicates time in months and the y-axis appears to indicate the number of observations. There are 100 censored observations. Unfortunately, without further information, it is not possible to provide a more detailed description or determine the subject matter.*

The given text seems to depict a graph indicating the survival time of two groups of patients: Fulvestrant+Ribociclib (N=484) and Fulvestrant+Placebo (N=242). The graph shows the number of patients still alive on the y-axis and the time since treatment on the x-axis. The patients in the Fulvestrant+Ribociclib group seem to have better survival outcomes and they have a higher number of patients that are still alive at the end of the graph at 26 months.*

The text describes the proportion of patients who are progression-free under different doses of Fulvestrant in a specific population. The text includes a graph that displays Progression Free Survival (ITT Population) over time (months) for Fulvestrant 260 mg and Fulvestrant 500 mg. The graph also includes the number of individuals at risk for each dose.*

This appears to be a graph representing the efficacy of two different dosages of a drug called Fulvestrant over a period of 80 months. The graph shows the percentage (%) of patients who remained on the drug for the duration of the study in relation to the time elapsed in months. The drug was administered at dosages of 500mg and 250mg. The number of patients who were "at risk" on each dosage at each time point is also displayed. There is a note indicating that no adjustments were made for multiplicity and the observations are not statistically significant.*